公开(公告)号：US20110207154A1

公开(公告)日：2011-08-25

申请号：US12974482

申请日：2010-12-21

申请人： JULES B. PUSCHETT ,  Daniel Romo ,  Luc R. Berghman ,  Daad Ali Abi-Ghanem ,  Xinzhong Lai

发明人： JULES B. PUSCHETT ,  Daniel Romo ,  Luc R. Berghman ,  Daad Ali Abi-Ghanem ,  Xinzhong Lai

IPC分类号： G01N33/566 ,  C07K14/00 ,  C07K14/765 ,  C07J19/00 ,  C07J43/00 ,  C07K14/435

CPC分类号： G01N33/9453 ,  C07J71/0021 ,  G01N33/531 ,  G01N33/566 ,  G01N33/6854

摘要： The present invention is directed toward a method for determination of marinobufagenin concentration in a body specimen through conjugation of marinobufagenin to a suitable protein, thereby creating a conjugate which will trigger an antibody response in a host. The conjugated marinobufagenin is immunogenic. The antibodies so produced may be employed in an ELISA test to ascertain the concentration of marinobufagenin in a body specimen. A number of unique compounds are created in the process and are disclosed. An ELISA assay may be employed.

摘要翻译： 本发明涉及一种通过将marinobufagenin与合适的蛋白质缀合来测定身体标本中的海因素基因蛋白浓度的方法，由此产生将在宿主中引发抗体反应的缀合物。 共轭马铃薯芽孢杆菌素是免疫原性的。 如此产生的抗体可用于ELISA试验，以确定人体标本中海马素原基因的浓度。 在该过程中产生了许多独特的化合物并被公开。 可以使用ELISA测定。

公开(公告)号：US20110008904A1

公开(公告)日：2011-01-13

申请号：US12781464

申请日：2010-05-17

申请人： JULES B. PUSCHETT

发明人： JULES B. PUSCHETT

IPC分类号： G01N33/50

CPC分类号： G01N33/743 ,  G01N2800/28 ,  Y10T436/142222

摘要： A method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the concentration of marinobufagenin to the concentration in such body specimens in normal persons, and if the marinobufagenin concentration is substantially above the concentration of a normal person, concluding traumatic brain injury exists. In a preferred embodiment, a substantial elevation is deemed to be an increase of about 30 percent above the marinobufagenin concentration of a normal person. The body specimen may be blood or urine. If a substantial elevation is deemed to exist, the magnitude from the departure from the concentration of a normal person may be employed in determining the timing and nature of treatment provided to the patient. The method may be repeated at predetermined intervals to monitor changes in the marinobufagenin with time. Corresponding apparatus is provided.

摘要翻译： 用于确定患者是否具有创伤性脑损伤的方法包括从患者获得身体标本，确定身体标本中海马素原基因的浓度，将正常人中的马氏原虫基因的浓度与这些身体标本中的浓度进行比较，如果 造血干细胞因子浓度大大高于正常人的浓度，结论创伤性脑损伤存在。 在一个优选的实施方案中，相当大的升高被认为比普通人的海因素原基因浓度高出约30％。 身体标本可能是血液或尿液。 如果认为存在实质性高程，则在确定提供给患者的治疗的时间和性质时，可以采用离开正常人集中的程度。 可以以预定的间隔重复该方法以随时间监测马铃薯白蛋白原的变化。 提供相应的设备。

公开(公告)号：US20110319372A1

公开(公告)日：2011-12-29

申请号：US13160735

申请日：2011-06-15

申请人： JULES B. PUSCHETT ,  LEE SHAPIRO

发明人： JULES B. PUSCHETT ,  LEE SHAPIRO

IPC分类号： A61K31/58 ,  A61P25/00 ,  G01N33/566

CPC分类号： G01N33/53 ,  A61K31/585 ,  G01N33/743 ,  G01N2800/28 ,  G01N2800/40

摘要： Known or suspected traumatic brain injuries may be treated therapeutically by administering a therapeutically effective dose of resibufogenin. A preferred method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the concentration of marinobufagenin to the concentration in such body specimens in normal patients, and if the marinobufagenin concentration is substantially above the concentration of a normal patient, concluding traumatic brain injury exists. In a preferred embodiment, a substantial elevation is deemed to be an increase of about 30 percent above the marinobufagenin concentration of a normal patient. The body specimen may be blood, urine, or cerebrospinal fluid. If a substantial elevation is deemed to exist, the magnitude of the departure from the concentration of a normal patient may be employed in determining the timing and nature of treatment provided to the patient. The method may be repeated at predetermined intervals to monitor changes in the marinobufagenin with time.

摘要翻译： 可以通过施用治疗有效剂量的抗纤维蛋白原治疗来治疗已知或怀疑的创伤性脑损伤。 用于确定患者是否具有创伤性脑损伤的优选方法包括从患者获得身体标本，确定身体标本中海马素原基因的浓度，将正常患者中的马氏原虫基因的浓度与这些身体标本中的浓度进行比较，以及如果 造血干细胞因子浓度明显高于正常患者的浓度，结论存在创伤性脑损伤。 在优选的实施方案中，认为实质高程比普通患者的海因素原基因浓度高出约30％。 身体标本可能是血液，尿液或脑脊液。 如果认为存在实质性高程，则在确定提供给患者的治疗的时间和性质时可以采用偏离正常患者浓度的大小。 可以以预定的间隔重复该方法以随时间监测马铃薯白蛋白原的变化。